Upgrade to SI Premium - Free Trial

Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen

September 8, 2026 9:34 AM
TD Cowen analyst Steve Scala raised the price target on Royalty Pharma (NASDAQ: RPRX) to $68.00 (from $65.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change